CO6561823A2 - Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas - Google Patents

Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas

Info

Publication number
CO6561823A2
CO6561823A2 CO12122679A CO12122679A CO6561823A2 CO 6561823 A2 CO6561823 A2 CO 6561823A2 CO 12122679 A CO12122679 A CO 12122679A CO 12122679 A CO12122679 A CO 12122679A CO 6561823 A2 CO6561823 A2 CO 6561823A2
Authority
CO
Colombia
Prior art keywords
quinolin
pyrrolo
pyrrolidin
dione
dihydro
Prior art date
Application number
CO12122679A
Other languages
English (en)
Spanish (es)
Inventor
David Reed
Neil R Barnes
Jhon F Kane
Christopher Lee
Jian Xie Chen
Martin P Redmon
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CO6561823A2 publication Critical patent/CO6561823A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO12122679A 2009-12-23 2012-07-23 Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas CO6561823A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
CO6561823A2 true CO6561823A2 (es) 2012-11-15

Family

ID=44188284

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12122679A CO6561823A2 (es) 2009-12-23 2012-07-23 Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas

Country Status (19)

Country Link
US (3) US8552192B2 (OSRAM)
EP (2) EP2515904A4 (OSRAM)
JP (2) JP2013515737A (OSRAM)
KR (2) KR101669707B1 (OSRAM)
CN (2) CN102834097B (OSRAM)
AU (2) AU2010336533B9 (OSRAM)
BR (1) BR112012015656A2 (OSRAM)
CA (1) CA2785503A1 (OSRAM)
CO (1) CO6561823A2 (OSRAM)
HK (1) HK1215025A1 (OSRAM)
MX (1) MX2012007259A (OSRAM)
MY (2) MY169232A (OSRAM)
NZ (2) NZ628087A (OSRAM)
PH (2) PH12012501293A1 (OSRAM)
RU (1) RU2556205C2 (OSRAM)
SG (1) SG181927A1 (OSRAM)
TW (3) TWI506026B (OSRAM)
WO (1) WO2011079142A2 (OSRAM)
ZA (1) ZA201204759B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1846406T1 (sl) * 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
CN102834097B (zh) * 2009-12-23 2015-06-17 艾科尔公司 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
US9180099B2 (en) * 2011-07-07 2015-11-10 Arqule Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
DK3665176T3 (da) * 2017-08-11 2024-03-25 Actuate Therapeutics Inc Faste former af 3-(5-fluorbenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrol-2,5-dion
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024513502A (ja) * 2021-04-07 2024-03-25 ユリカ セラピューティクス インコーポレイテッド Urat1阻害剤、医薬組成物及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
EP1242420A2 (en) * 1999-12-16 2002-09-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
WO2004013069A1 (en) * 2002-07-31 2004-02-12 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
SI1846406T1 (sl) 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
WO2009002807A2 (en) * 2007-06-22 2008-12-31 Arqule, Inc. Indolyl pyrrolidines for the treatment of cancer
CN101801961B (zh) 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
CN102834097B (zh) * 2009-12-23 2015-06-17 艾科尔公司 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法

Also Published As

Publication number Publication date
NZ628087A (en) 2016-02-26
EP3081567A3 (en) 2016-11-16
WO2011079142A2 (en) 2011-06-30
PH12012501293A1 (en) 2013-01-07
BR112012015656A2 (pt) 2016-05-10
MY169232A (en) 2019-03-19
RU2012131344A (ru) 2014-01-27
US8871933B2 (en) 2014-10-28
KR20160121602A (ko) 2016-10-19
US8552192B2 (en) 2013-10-08
JP2016041712A (ja) 2016-03-31
CA2785503A1 (en) 2011-06-30
TWI506026B (zh) 2015-11-01
ZA201204759B (en) 2014-03-26
US20140031551A1 (en) 2014-01-30
TW201141865A (en) 2011-12-01
AU2015243015B2 (en) 2017-02-02
WO2011079142A3 (en) 2011-11-24
EP3081567A2 (en) 2016-10-19
MY156701A (en) 2016-03-15
CN104910159A (zh) 2015-09-16
HK1215025A1 (zh) 2016-08-12
JP2013515737A (ja) 2013-05-09
AU2010336533B2 (en) 2015-09-10
US9499540B2 (en) 2016-11-22
EP2515904A2 (en) 2012-10-31
US20160024076A1 (en) 2016-01-28
RU2556205C2 (ru) 2015-07-10
TW201542546A (zh) 2015-11-16
AU2010336533B9 (en) 2015-10-08
NZ600800A (en) 2014-10-31
EP2515904A4 (en) 2013-07-03
CN102834097B (zh) 2015-06-17
KR101669707B1 (ko) 2016-10-27
MX2012007259A (es) 2015-05-15
AU2015243015A1 (en) 2015-11-05
AU2010336533A1 (en) 2012-07-12
SG181927A1 (en) 2012-07-30
PH12014500310A1 (en) 2015-09-28
TWI557125B (zh) 2016-11-11
US20110160242A1 (en) 2011-06-30
TW201643163A (zh) 2016-12-16
CN102834097A (zh) 2012-12-19
KR20120113760A (ko) 2012-10-15

Similar Documents

Publication Publication Date Title
CO6561823A2 (es) Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
NZ600430A (en) Spiro-oxindole mdm2 antagonists
WO2011082266A3 (en) Substituted heterocyclic compounds
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
EA201071320A1 (ru) Активаторы глюкокиназы
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
WO2009002807A3 (en) Indolyl pyrrolidines for the treatment of cancer
ATE538105T1 (de) Substituierte tetrazolverbindungen und ihre verwendung
WO2011082271A3 (en) Substituted triazolo-pyrimidine compounds
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
WO2012088491A3 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
WO2011082269A3 (en) Substituted benzo-pyrimido-tetrazolo-diazepine compounds
MY148385A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer

Legal Events

Date Code Title Description
FG Application granted